Beta-blockers (β-blockers) reduce morbidity and mortality in many disease states, but had
been considered contraindicated in chronic obstructive pulmonary disease (COPD), due to …

Abstract β-Blockers are competitive antagonists at β-adrenergic receptors (β-AR) and are a
life-saving form of treatment in different cardiovascular diseases (CVD). Despite current …

Chronic obstructive pulmonary disease (COPD) with cardiovascular complications is very
common. Due to fear of exacerbating airway spasm, β-blockers are rarely used in such …

Treating people with cardiovascular disease and COPD causes significant clinician anxiety.
β-Blockers save lives in people with heart disease, specifically postinfarction and heart …

The use of β-blockers is generally well tolerated and effective in COPD patients, who also
have a clear cardiovascular indication for these drugs. However, they should not be used in …

OBJECTIVE: To evaluate the safety and cardiovascular benefits of β-blocker therapy in
patients with chronic obstructive pulmonary disease (COPD). DATA SOURCES: Clinical …

Introduction: The use of beta-blockers in chronic obstructive pulmonary disease (COPD) is
controversial, primarily due to concerns that they may worsen lung function and attenuate …

Background β-Adrenergic agonists exert physiologic effects that are the opposite of those of
β-blockers. β-Blockers are known to reduce morbidity and mortality in patients with cardiac …

Chronic obstructive pulmonary disease is prevalent condition commonly associated with
cardiovascular diseases. When both are combined the prognosis of the patient worsens …

Cardiovascular diseases are major public health problems. ßblockers therapy is indicated
for the majority of patients with heart failure and coronary artery disease (Class I, Level of …